Cannabigerol (CBG), a non-psychoactive compound found in cannabis, has been garnering increasing attention for its potential anti-cancer properties. In the 1960s, renowned Israeli Professor Raphael Mechoulam, widely recognized as the “Father of Cannabis Research,” along with his partner Yehiel Gaoni, made the discovery of CBGA - among other amazing discoveries through the years.
CBGA, which stands for cannabigerolic acid, is an essential cannabinoid present in raw cannabis plants. Its significance lies in being the precursor to all other cannabinoids, earning it the well-deserved title of the “Mother of All Cannabinoids.”
CBGA plays a pivotal role in the synthesis of three primary cannabinoids: tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), and cannabichromenic acid (CBCA). Through a process called decarboxylation, wherein heat or light exposure occurs, THCA, CBDA, and CBCA undergo a chemical transformation, becoming the more well known THC, CBD, and CBC, respectively.
However, in the case of CBGA, specific enzymes facilitate its immediate conversion into THCA, CBDA, or CBCA. This distinctive mechanism of interaction and synthesis explains the inverse relationship between THC and CBG levels, where an increase in THC results in a decrease in CBG.
While cannabinoids like CBD and THC have taken the spotlight, what sets CBG apart is its unique ability to interact with the endocannabinoid system and produce various therapeutic effects without inducing euphoric, or impairing, effects.
Exploring CBG's Role in Fighting Cancer: An Overview of Recent Studies
One of the fascinating pathways through which CBG exerts its anti-cancer effects is the TRPM8 ion channel. Research has shown that CBG may tap into this channel, inhibiting the growth of tumors associated with prostate, melanoma, colorectal, and bladder cancers.
Breast cancer has also been a subject of interest in CBG research. When combined with other cannabinoids, CBG has shown the ability to stimulate tumor-deactivating responses, making it potentially effective against breast cancer cells. A study published in the Anticancer Research journal revealed that CBG, in combination with other cannabinoids, displayed promising results in inhibiting the growth of breast cancer cells.
Furthermore, CBG has demonstrated its effectiveness in combating stomach and bone cancers. A study conducted by researchers at an Israel based cannabis medicine developer found that CBG is more potent than its raw form, CBGA, in suppressing the growth of stomach and bone cancer cells. This discovery opens up new possibilities for developing CBG-based therapies targeted at these specific cancer types.
Glioblastoma, a particularly aggressive and therapy-resistant form of brain cancer, has been a major challenge in the field of oncology. However, CBG offers a glimmer of hope. Research published in the journal Cells revealed that CBG has the potential to destroy therapy-resistant glioblastoma stem cells, which are the root cause of cancer development and highly resistant to conventional treatments.
In addition to the aforementioned cancers, CBG has shown promise in combating other types of cancer as well. Previous investigations have found that CBG exhibits antitumor activity against melanoma growths and oral epithelial carcinoma cells, further expanding its potential applications in cancer treatment.
CBG and its Anti-Cancer Effects: Separating Fact from Fiction
While these findings are undoubtedly promising, it is important to note that there are currently no human clinical trials to fully confirm CBG's anticancer potential.
As the research on CBG and its anti-cancer effects continues to evolve, it is essential for consumers to stay informed about the efficacy of CBG products on the market. Understanding the results of animal-based studies can help individuals make informed decisions regarding CBG and its potential role in their healing journey.
In conclusion, CBG has emerged as a promising cannabinoid in the field of cancer treatment. Its ability to interact with the endocannabinoid system and target specific pathways involved in tumor growth and resistance makes it an intriguing candidate for future therapeutic developments. However, more extensive research, including human clinical trials, is needed to fully validate CBG's effectiveness as a cancer-fighting agent. Until then, it is crucial to approach CBG with caution, seeking professional guidance, and making informed choices in exploring potential cannabinoid treatments for cancer.
If you’d like to know how CBG could help you on your healing journey, please find a time that works for you: